Literature DB >> 20522307

Mechanisms of recurrence of Ta/T1 bladder cancer.

Richard T Bryan1, Stuart I Collins, Mark C Daykin, Maurice P Zeegers, K K Cheng, D Michael A Wallace, Graham M Sole.   

Abstract

INTRODUCTION: Bladder cancer recurrence occurs via four mechanisms - incomplete resection, tumour cell re-implantation, growth of microscopic tumours, and new tumour formation. The first two mechanisms are influenced by clinicians before and immediately after resection; the remaining mechanisms have the potential to be influenced by chemopreventive agents. However, the relative importance and timing of these mechanisms is currently unknown. Our objective was to postulate the incidence and timing of these mechanisms by investigating the location of bladder cancer recurrences over time. PATIENTS AND METHODS: The topographical locations of tumours and their recurrences were analysed retrospectively for 169 patients newly-diagnosed with Ta/T1 bladder cancer, with median follow-up of 33.8 months. Tumours were assigned to one or more of six bladder sectors, and time to recurrence and location of recurrences were recorded.
RESULTS: Median time to first tumour recurrence was 40 months. Median times between subsequent recurrences were 6.6, 7.9, 8.0 and 6.6 months for recurrences 1 to 2, 2 to 3, 3 to 4, and 4 to 5, respectively. The risk of first tumour recurrence in any given bladder sector increased by nearly 4-fold if the primary tumour was resected from that sector (P < 0.001); this association was not significant for subsequent recurrences. The proportion of tumour recurrences in multiple bladder sectors increased from 13% for the first recurrence to 100% for recurrence seven onwards.
CONCLUSIONS: First tumour recurrence appears different to subsequent recurrences; incomplete resection and tumour cell reimplantation may dominate at this time-point. Only later does genuine new tumour formation appear to increase in importance. This has important implications for clinical trials, especially those involving chemopreventive agents.

Entities:  

Mesh:

Year:  2010        PMID: 20522307      PMCID: PMC3182798          DOI: 10.1308/003588410X12664192076935

Source DB:  PubMed          Journal:  Ann R Coll Surg Engl        ISSN: 0035-8843            Impact factor:   1.891


  30 in total

Review 1.  Molecular pathways in bladder cancer: part 2.

Authors:  Richard T Bryan; Syed A Hussain; Nicholas D James; Janusz A Jankowski; D Michael A Wallace
Journal:  BJU Int       Date:  2005-03       Impact factor: 5.588

Review 2.  Carcinoma of the urinary bladder: a review of its diverse morphology.

Authors:  J N Eble; R H Young
Journal:  Semin Diagn Pathol       Date:  1997-05       Impact factor: 3.464

3.  Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: a combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function.

Authors:  S Hinotsu; H Akaza; Y Ohashi; T Kotake
Journal:  Cancer       Date:  1999-11-01       Impact factor: 6.860

4.  Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup.

Authors:  E Solsona; I Iborra; J V Ricós; J L Monrós; J Casanova; R Dumont
Journal:  J Urol       Date:  1999-04       Impact factor: 7.450

5.  The effect of intravesical mitomycin C on the recurrence of superficial (Ta-T1) bladder cancer. A Hungarian Multicenter Study.

Authors:  J Kondás; L Kiss; A Határ; A Kiss; T Lukács; P Szeldeli; F Törzsök; I Bodrogi
Journal:  Int Urol Nephrol       Date:  1999       Impact factor: 2.370

6.  Significance of bladder biopsies in Ta,T1 bladder tumors: a report from the EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTC-GU Group Superficial Bladder Committee.

Authors:  A van der Meijden; W Oosterlinck; M Brausi; K H Kurth; R Sylvester; C de Balincourt
Journal:  Eur Urol       Date:  1999-04       Impact factor: 20.096

7.  Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

Authors:  Richard J Sylvester; Adrian P M van der Meijden; Willem Oosterlinck; J Alfred Witjes; Christian Bouffioux; Louis Denis; Donald W W Newling; Karlheinz Kurth
Journal:  Eur Urol       Date:  2006-01-17       Impact factor: 20.096

8.  Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer?

Authors:  Luigi Schips; Herbert Augustin; Richard E Zigeuner; Guenter Gallé; Helga Habermann; Harald Trummer; Karl Pummer; Gerhart Hubmer
Journal:  Urology       Date:  2002-02       Impact factor: 2.649

Review 9.  Molecular pathogenesis of bladder cancer.

Authors:  Margaret A Knowles
Journal:  Int J Clin Oncol       Date:  2008-08-15       Impact factor: 3.402

10.  Narrow-band imaging flexible cystoscopy in the detection of recurrent urothelial cancer of the bladder.

Authors:  Richard T Bryan; Lucinda J Billingham; D Michael A Wallace
Journal:  BJU Int       Date:  2007-11-13       Impact factor: 5.588

View more
  23 in total

Review 1.  Recurrence mechanisms of non-muscle-invasive bladder cancer - a clinical perspective.

Authors:  Jeremy Yuen-Chun Teoh; Ashish M Kamat; Peter C Black; Petros Grivas; Shahrokh F Shariat; Marek Babjuk
Journal:  Nat Rev Urol       Date:  2022-03-31       Impact factor: 16.430

2.  Serine/threonine kinase 32C is overexpressed in bladder cancer and contributes to tumor progression.

Authors:  Erlin Sun; Kangkang Liu; Kun Zhao; Lining Wang
Journal:  Cancer Biol Ther       Date:  2018-10-25       Impact factor: 4.742

3.  Correlation of tumor-infiltrating lymphocytes with bladder cancer recurrence in patients with solitary low-grade urothelial carcinoma.

Authors:  Kristian Krpina; Emina Babarović; Nives Jonjić
Journal:  Virchows Arch       Date:  2015-07-28       Impact factor: 4.064

Review 4.  The role of urine markers, white light cystoscopy and fluorescence cystoscopy in recurrence, progression and follow-up of non-muscle invasive bladder cancer.

Authors:  Ilhan Karaoglu; Antoine G van der Heijden; J Alfred Witjes
Journal:  World J Urol       Date:  2013-10-29       Impact factor: 4.226

5.  [T1 bladder cancer: role of documentation for bladder tumor findings and targeted second resection].

Authors:  D A Lazica; S Böttcher; S Degener; F-C von Rundstedt; A S Brandt; S Störkel; S Roth
Journal:  Urologe A       Date:  2013-08       Impact factor: 0.639

Review 6.  The effects and effectiveness of electromotive drug administration and chemohyperthermia for treating non-muscle invasive bladder cancer.

Authors:  S E Slater; P Patel; R Viney; M Foster; E Porfiri; N D James; B Montgomery; R T Bryan
Journal:  Ann R Coll Surg Engl       Date:  2014-09       Impact factor: 1.891

Review 7.  Emerging endoscopic and photodynamic techniques for bladder cancer detection and surveillance.

Authors:  Prashant Patel; Richard T Bryan; D Michael A Wallace
Journal:  ScientificWorldJournal       Date:  2011-12-29

8.  DNA Methylation profiles as predictors of recurrence in non muscle invasive bladder cancer: an MS-MLPA approach.

Authors:  Valentina Casadio; Chiara Molinari; Daniele Calistri; Michela Tebaldi; Roberta Gunelli; Luigi Serra; Fabio Falcini; Chiara Zingaretti; Rosella Silvestrini; Dino Amadori; Wainer Zoli
Journal:  J Exp Clin Cancer Res       Date:  2013-11-19

9.  Copy number analysis of 24 oncogenes: MDM4 identified as a putative marker for low recurrence risk in non muscle invasive bladder cancer.

Authors:  Samanta Salvi; Daniele Calistri; Giorgia Gurioli; Elisa Carretta; Luigi Serra; Roberta Gunelli; Wainer Zoli; Valentina Casadio
Journal:  Int J Mol Sci       Date:  2014-07-14       Impact factor: 5.923

10.  Toward Personalised Liquid Biopsies for Urothelial Carcinoma: Characterisation of ddPCR and Urinary cfDNA for the Detection of the TERT 228 G>A/T Mutation.

Authors:  Ilaria J Russo; Yongwon Ju; Naheema S Gordon; Maurice P Zeegers; K K Cheng; Nicholas D James; Richard T Bryan; Douglas G Ward
Journal:  Bladder Cancer       Date:  2018-01-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.